PTPLA Activators
PTPLA Activators encompass a variety of chemical compounds that indirectly enhance the functional activity of PTPLA through distinct signaling pathways. Forskolin, through its activation of adenylyl cyclase and subsequent increase in cAMP, indirectly boosts PTPLA activity by facilitating protein kinase A (PKA) phosphorylation of PTPLA or associated regulatory proteins. Similarly, PMA, by activating PKC, may enhance PTPLA's functional activity through phosphorylation mechanisms. Ionomycin, by raising intracellular calcium levels, can activate calcium-dependent protein kinases that may target PTPLA for phosphorylation, thereby enhancing its activity. Sphingosine-1-phosphate, via its receptor-mediated signaling, has the potential to activate kinases that could phosphorylate and activate PTPLA, while isoproterenol, as a β-adrenergic agonist, raises cAMP levels which can lead to PKA-mediated phosphorylation of PTPLA.
The EGCG kinase inhibitor might indirectly increase PTPLA activity by inhibiting kinases that negatively regulate it, just as A23187 functions as a calcium ionophore that could activate PTPLA through calcium-dependent kinases. Sildenafil, which inhibits phosphodiesterase to maintain cAMP levels, could lead to enhanced PKA activity and subsequent PTPLA activation. Anisomycin, by activating JNK signaling, might promote PTPLA activity through JNK-specific substrate phosphorylation. Lastly, Zoledronic acid, with its unique mechanism of inhibiting farnesyl pyrophosphate synthase, could affect protein prenylation and localization within cellular signaling pathways, thus indirectly promoting PTPLA activity by affecting the spatial dynamics of its signaling network.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular levels of cAMP. Elevated cAMP activates PKA, which can then phosphorylate PTPLA, potentially enhancing its activity by altering its interaction with other proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is known to phosphorylate a wide range of target proteins. PKC-mediated phosphorylation of PTPLA could enhance its catalytic activity or its interaction with substrates. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent protein kinases that may phosphorylate and activate PTPLA. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine-1-phosphate receptors, leading to downstream signaling pathways that may include the activation of kinases capable of phosphorylating and activating PTPLA. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a β-adrenergic agonist that increases cAMP levels, leading to activation of PKA. PKA could enhance the activity of PTPLA by phosphorylation at specific serine/threonine residues. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may inhibit kinases that negatively regulate PTPLA, thereby indirectly increasing PTPLA activity by lifting the inhibitory phosphorylation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium and may activate calcium-dependent kinases, potentially leading to the activation of PTPLA. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator that might lead to the phosphorylation of substrates, including PTPLA, indirectly enhancing its activity through JNK-mediated signaling pathways. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid inhibits farnesyl pyrophosphate synthase, potentially affecting prenylation and localization of proteins in signaling pathways that may involve PTPLA, leading to its functional enhancement. | ||||||